The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin

Toxicology and Applied Pharmacology

Volumn 336, Issue , 2017, Pages 40-48

  Veith, C ^a   Drent, M ^a,b   Bast, A ^a   van Schooten, F J ^a   Boots, A W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Antioxidants; Idiopathic pulmonary fibrosis (IPF); Inflammation; Interstitial lung diseases (ILD); Oxidative stress; Quercetin

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; FLAVONOID; GLUTATHIONE; GLUTATHIONE DISULFIDE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PREDNISONE; QUERCETIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; URIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BLEOMYCIN; IL8 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEAS-2B CELL LINE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; CASE CONTROL STUDY; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; LUNG; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLEOMYCIN; CASE-CONTROL STUDIES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; LUNG; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; QUERCETIN; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85031739798     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2017.10.001     Document Type: Article

References (60)

1. Arts, Mariken J.T.J., Sebastiaan Dallinga, J., Voss, Hans-Peter, Haenen, Guido R.M.M., Bast, Aalt, A new approach to assess the total antioxidant capacity using the TEAC assay. Food Chem. 88:4 (2004), 567–570.
2. Bast, A., Haenen, G.R., Doelman, C.J., Oxidants and antioxidants: state of the art. Am. J. Med. 91:3C (1991 Sep 30), 2S–13S.
3. Bast, A., Weseler, A.R., Haenen, G.R., den Hartog, G.J., Oxidative stress and antioxidants in interstitial lung disease. Curr. Opin. Pulm. Med. 16:5 (2010 Sep), 516–520.
4. Boots, A.W., Wilms, L.C., Swennen, E.L., Kleinjans, J.C., Bast, A., Haenen, G.R., In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24:7–8 (2008 Jul-Aug), 703–710.
5. Boots, A.W., Drent, M., Swennen, E.L., Moonen, H.J., Bast, A., Haenen, G.R., Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir. Med. 103:3 (2009 Mar), 364–372.
6. Boots, A.W., Drent, M., de Boer, V.C., Bast, A., Haenen, G.R., Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr. 30:4 (2011 Aug), 506–512.
7. Bringardner, B.D., Baran, C.P., Eubank, T.D., Marsh, C.B., The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 10:2 (2008 Feb), 287–301.
8. Cheresh, P., Kim, S.J., Tulasiram, S., Kamp, D.W., Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta 1832:7 (2013 Jul), 1028–1040.
9. Cho, H.Y., Reddy, S.P., Kleeberger, S.R., Nrf2 defends the lung from oxidative stress. Antioxid. Redox Signal. 8:1–2 (2006 Jan-Feb), 76–87.
10. D'Andrea, G., Quercetin: a flavonol with multifaceted therapeutic applications?. Fitoterapia 106 (2015 Oct), 256–271.
11. Fischer, M.A., Gransier, T.J., Beckers, L.M., Bekers, O., Bast, A., Haenen, G.R., Determination of the antioxidant capacity in blood. Clin. Chem. Lab. Med. 43:7 (2005), 735–740.
12. de Franceschi, L., Turrini, F., Honczarenko, M., Ayi, K., Rivera, A., Fleming, M.D. et al., In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica 89:11 (2004 Nov), 1287–1298 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
13. Gardi, C., Bauerova, K., Stringa, B., Kuncirova, V., Slovak, L., Ponist, S. et al., Quercetin reduced inflammation and increased antioxidant defense in rat adjuvant arthritis. Arch. Biochem. Biophys. 583 (2015 Oct 1), 150–157.
14. Gauliard, B., Grieve, D., Wilson, R., Crozier, A., Jenkins, C., Mullen, W.D. et al., The effects of dietary phenolic compounds on cytokine and antioxidant production by A549 cells. J. Med. Food 11:2 (2008 Jun), 382–384.
15. Glorieux, C., Zamocky, M., Sandoval, J.M., Verrax, J., Calderon, P.B., Regulation of catalase expression in healthy and cancerous cells. Free Radic. Biol. Med. 87 (2015 Oct), 84–97 [Review].
16. Gunay, E., Celik, S., Sarinc-Ulasli, S., Ozyurek, A., Hazman, O., Gunay, S. et al., Comparison of the anti-inflammatory effects of Proanthocyanidin, quercetin, and damnacanthal on benzo(a)pyrene exposed A549 alveolar cell line. Inflammation 39:2 (2016 Apr), 744–751 [Research Support, Non-U.S. Gov't].
17. Hay, J., Shahzeidi, S., Laurent, G., Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 65:2 (1991), 81–94 [Research Support, Non-U.S. Gov't Review].
18. Hayashi, Y., Matsushima, M., Nakamura, T., Shibasaki, M., Hashimoto, N., Imaizumi, K. et al., Quercetin protects against pulmonary oxidant stress via heme oxygenase-1 induction in lung epithelial cells. Biochem. Biophys. Res. Commun. 417:1 (2012 Jan 6), 169–174.
19. Hecker, L., Cheng, J., Thannickal, V.J., Targeting NOX enzymes in pulmonary fibrosis. Cell. Mol. Life Sci. 69:14 (2012 Jul), 2365–2371.
20. Huang, R., Zhong, T., Quercetin, Wu H., protects against lipopolysaccharide-induced acute lung injury in rats through suppression of inflammation and oxidative stress. Arch. Med. Sci. 11:2 (2015 Apr 25), 427–432.
21. Impellizzeri, D., Talero, E., Siracusa, R., Alcaide, A., Cordaro, M., Maria Zubelia, J. et al., Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice. Br. J. Nutr. 114:6 (2015 Sep 28), 853–865.
22. Kandhare, A.D., Mukherjee, A., Ghosh, P., Bodhankar, S.L., Efficacy of antioxidant in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Excli J. 15 (2016), 636–651 [Review].
23. King, T.E. Jr., Pardo, A., Selman, M., Idiopathic pulmonary fibrosis. Lancet 378:9807 (2011 Dec 3), 1949–1961.
24. Klimaszewska-Wisniewska, A., Halas-Wisniewska, M., Izdebska, M., Gagat, M., Grzanka, A., Grzanka, D., Antiproliferative and antimetastatic action of quercetin on A549 non-small cell lung cancer cells through its effect on the cytoskeleton. Acta Histochem. 119:2 (2017 Mar), 99–112.
25. Kliment, C.R., Oury, T.D., Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 49:5 (2010 Sep 1), 707–717.
26. Kuwano, K., Nakashima, N., Inoshima, I., Hagimoto, N., Fujita, M., Yoshimi, M. et al., Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur. Respir. J. 21:2 (2003 Feb), 232–240.
27. Lenz, A.G., Costabel, U., Maier, K.L., Oxidized BAL fluid proteins in patients with interstitial lung diseases. Eur. Respir. J. 9:2 (1996 Feb), 307–312.
28. Meltzer, E.B., Noble, P.W., Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis., 3, 2008, 8.
29. Mossman, B.T., Lounsbury, K.M., Reddy, S.P., Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am. J. Respir. Cell Mol. Biol. 34:6 (2006 Jun), 666–669.
30. Mukaida, N., Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell Mol. Physiol. 284:4 (2003 Apr), L566–77 [Review].
31. Nakamura, T., Matsushima, M., Hayashi, Y., Shibasaki, M., Imaizumi, K., Hashimoto, N. et al., Attenuation of transforming growth factor-beta-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am. J. Respir. Cell Mol. Biol. 44:5 (2011 May), 614–620.
32. Navaratnam, V., Fleming, K.M., West, J., Smith, C.J., Jenkins, R.G., Fogarty, A. et al., The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66:6 (2011 Jun), 462–467.
33. Numazawa, S., Yoshida, T., Nrf2-dependent gene expressions: a molecular toxicological aspect. J. Toxicol. Sci. 29:2 (2004 May), 81–89.
34. Park, H.J., Lee, C.M., Jung, I.D., Lee, J.S., Jeong, Y.I., Chang, J.H. et al., Quercetin regulates Th1/Th2 balance in a murine model of asthma. Int. Immunopharmacol. 9:3 (2009 Mar), 261–267 [Research Support, Non-U.S. Gov't].
35. Piguet, P.F., Collart, M.A., Grau, G.E., Kapanci, Y., Vassalli, P., Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170:3 (1989 Sep 1), 655–663.
36. Quanjer, P.H., Tammeling, G.J., Cotes, J.E., Pedersom, O.F., Peslin, R., Yernaut, J.C., Lung volumes and forced ventilatory flows. Report working party. Standardization of lung functions tests. European Commission for Steel and Coal. Official statement of the European Respiratory Society. Eur. Respir. J. 16 (1993), 5–40.
37. Rafii, R., Juarez, M.M., Albertson, T.E., Chan, A.L., A review of current and novel therapies for idiopathic pulmonary fibrosis. J. Thorac. Dis. 5:1 (2013 Feb), 48–73.
38. Raghu, G., Brown, K.K., Costabel, U., Cottin, V., du Bois, R.M., Lasky, J.A. et al., Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178:9 (2008 Nov 1), 948–955.
39. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K. et al., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011 Mar 15), 788–824.
40. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K. et al., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011 Mar 15), 788–824 [Practice Guideline Research Support, Non-U.S. Gov't].
41. Raghu, G., Chen, S.Y., Yeh, W.S., Maroni, B., Li, Q., Lee, Y.C. et al., Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2:7 (2014 Jul), 566–572.
42. Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C.A., Azuma, A., Behr, J. et al., An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 192:2 (2015 Jul 15), e3–19.
43. Rahman, T., Hosen, I., Towhidul Islam, M.M., Shekhar, H.U., Oxidative stress and human health. Adv. Biosci. Biotechnol. 3 (2012), 997–1019.
44. Ren, J., Li, J., Liu, X., Feng, Y., Gui, Y., Yang, J. et al., Quercetin inhibits fibroblast activation and kidney fibrosis involving the suppression of mammalian target of rapamycin and beta-catenin signaling. Sci. Rep., 6, 2016, 23968.
45. Schuliga, M., NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules 5:3 (2015), 1266–1283.
46. Singh, S., Vrishni, S., Singh, B.K., Rahman, I., Kakkar, P., Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 44:11 (2010 Nov), 1267–1288.
47. Singh, S., Vrishni, S., Singh, B.K., Rahman, I., Kakkar, P., Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 44:11 (2010 Nov), 1267–1288.
48. Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E.H. et al., Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev., 9, 2010, CD003134.
49. Surh, Y.J., Kundu, J.K., Na, H.K., Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 74:13 (2008 Oct), 1526–1539.
50. Swamy, S.M., Rajasekaran, N.S., Thannickal, V.J., Nuclear factor-Erythroid-2-related factor 2 in aging and lung fibrosis. Am. J. Pathol. 186:7 (2016 Jul), 1712–1723.
51. Swennen, E.L., Bast, A., Dagnelie, P.C., Immunoregulatory effects of adenosine 5′-triphosphate on cytokine release from stimulated whole blood. Eur. J. Immunol. 35:3 (2005 Mar), 852–858.
52. Takashima, K., Matsushima, M., Hashimoto, K., Nose, H., Sato, M., Hashimoto, N. et al., Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury. Respir. Res., 15, 2014 Nov 21, 150.
53. Tao, J., Wei, Y., Hu, T., Flavonoids of Polygonum hydropiper L. attenuates lipopolysaccharide-induced inflammatory injury via suppressing phosphorylation in MAPKs pathways. BMC Complement Altern. Med., 16, 2016 Jan 22, 25.
54. Ushio-Fukai, M., Nakamura, Y., Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 266:1 (2008 Jul 18), 37–52.
55. Vancheri, C., Failla, M., Crimi, N., Raghu, G., Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 35:3 (2010 Mar), 496–504.
56. Wang, L., Chen, J., Wang, B., Wu, D., Li, H., Lu, H. et al., Protective effect of quercetin on lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammatory cell influx. Exp. Biol. Med. (Maywood) 239:12 (2014 Dec), 1653–1662.
57. Warnakulasuriya, S.N., Ziaullah, Rupasinghe H.P., Novel long chain fatty acid derivatives of quercetin-3-O-glucoside reduce cytotoxicity induced by cigarette smoke toxicants in human fetal lung fibroblasts. Eur. J. Pharmacol. 781 (2016 Jun 15), 128–138.
58. Woodcock, H.V., Maher, T.M., The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep., 6, 2014, 16.
59. Ziegenhagen, M.W., Zabel, P., Zissel, G., Schlaak, M., Muller-Quernheim, J., Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am. J. Respir. Crit Care Med. 157:3 Pt 1 (1998 Mar), 762–768 [Comparative Study Research Support, Non-U.S. Gov't].
60. Zoz, D.F., Lawson, W.E., Blackwell, T.S., Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 341:6 (2011 Jun), 435–438.